T cells play a pivotal role in the initiation and progression of multiple sclerosis. We have found that 1,4-aryl-2-mercaptoimidazole (KRM-III) inhibited T-cell antigen receptor-and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC 50 of 5 M. The KRM-III-mediated inhibitory effect was specific for NFAT activation but not for nuclear factor B. Oral administration of 90 mg/kg KRM-III resulted in complete abrogation of anti-CD3 antibody-induced T-cell activation and a 45.8% reduction in footpad swelling in bovine serum albumininduced delayed-type hypersensitivity. In the murine experimental autoimmune encephalomyelitis (EAE) model, oral administration of KRM-III significantly attenuated the severity of disease when given before or after disease onset. Draining lymph node cells from KRM-III-treated mice showed markedly reduced proliferation in response to myelin oligodendrocyte glycoprotein peptide. Histological analysis indicated that KRM-III reduced the infiltration of inflammatory cells to the white matter of spinal lumbar cords. These results demonstrate that KRM-III efficiently inhibits T-cell activation and inflammatory responses and lessens EAE clinical signs, which suggest KRM-III as a potential lead compound for the treatment of T-celldriven autoimmune diseases.
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system, which is characterized by inflammatory lesions consisting of T cells, B cells, and macrophages in the white matter of the central nervous system (Raine, 1984) . Although the etiology is not well known, MS has been considered as a CD4 T cell-dependent disease (Steinman, 2001; Hafler, 2004) . This notion is based on the genetic linkage of MS susceptibility with major histocompatibility complex II genes (Zamvil and Steinman, 1990) and the high frequency of activated, myelin-reactive T cells in the periphery as well as cerebrospinal fluid of MS patients (Traugott et al., 1983; Hauser et al., 1986 ). An early study demonstrated that transgenic mice expressing myelin-specific T-cell antigen receptor (TCR) spontaneously developed demyelinating disease, suggesting that myelin-specific T cells might be one of the causative agents of MS and can initiate the inflammatory disease process (Goverman et al., 1993) . Moreover, the experimental autoimmune encephalomyelitis (EAE) model, an animal model of human MS, was induced by immunizing genetically susceptible animals with myelin peptides or myelin antigens, including myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein (MOG), or by adoptively transferring myelin-reactive T cells (Zamvil et al., 1985a,b; McRae et al., 1992) .
In the mouse model of relapsing MS, the immunodominant epitope or immunodominant antigen changes continuously as relapses go on, i.e., epitope spreading (McRae et al., 1995; Yu et al., 1996; Tuohy et al., 1999; Vanderlugt and Miller, 2002) . Tolerance induction to the relapse-associated epitope blocked disease progression, implicating a prime role of T cells in initiating and propagating MS (Vanderlugt et al., 2000) . There are also several lines of evidence that epitope spreading occurs in human patients with MS, suggesting that the mouse MS models represent many aspects of human MS, and, therefore, inhibition of T-cell activation would be beneficial for the treatment of MS (Tuohy et al., 1997 (Tuohy et al., , 1999a Goebels et al., 2000) .
In this study, we screened out 1,4-aryl-2-mercaptoimidazole (KRM-III) as a potential T-cell inhibitor based on its inhibitory effect on TCR-induced nuclear factor of activated T cells (NFAT) activation in Jurkat T cells, and we further demonstrated its T-cell inhibitory effect in vitro and in vivo. To determine its potential use for the treatment of T celldependent autoimmune diseases, we evaluated the KRM-III effect on disease progression and clinical severity in delayedtype hypersensitivity (DTH) and murine model of human MS, EAE.
Materials and Methods
Animals, Compounds, and Peptides. Six-to 10-week-old BALB/c and C57BL/6 female mice were purchased from the Orientbio (Sungnam, Korea). All mice were housed in a specific pathogenfree facility in accordance with institutional health guidelines, and animal studies were reviewed and approved by the institutional review committee. KRM-III was synthesized at the Korea Research Institute of Chemical Technology (Daejeon, Korea). For in vitro assays, KRM-III was dissolved in dimethylsulfoxide, diluted, and added to cells at the indicated concentration with final dimethylsulfoxide concentration of less than 0.5%. For oral administration, KRM-III or cyclosporine A (CsA) (Calbiochem, San Diego, CA) was suspended in 0.2% carboxyl methyl cellulose (CMC). MOG 35-55 peptide (MEVGWYRSPFSRVVHL YRNGK) was synthesized by Peptron (Daejeon, Korea). The purity of peptides was greater than 95% as determined by high-performance liquid chromatography (HPLC).
Reporter Assays. Jurkat T cells (5 ϫ 10 5 cells/ml) transiently transfected with reporter plasmids were preincubated with various concentrations of KRM-III (0ϳ50 M) for 3 h and activated with precoated anti-CD3 antibody [(Ab) 1 g/ml] (UCHT1; BD Pharmingen, San Jose, CA) or phorbol myristate acetate (PMA; 5 ng/ml) plus ionomycin (500 ng/ml) (Sigma-Aldrich, St. Louis, MO). Jurkat cells were further incubated for 24 h, harvested, lysed, centrifuged, and assayed for luciferase activity (Microsoft Plus; Berthold Technologies, Bad Wildbad, Germany). The NFAT reporter plasmid consists of three tandem repeats of NFAT binding sites (dNFAT-NFAP) and minimal promoter regions from the interleukin (IL)-2 promoter (kindly given by Dr. G. Crabtree, Stanford University, Stanford, CA). Nuclear factor B (NF-B) reporter plasmid was purchased from Stratagene (La Jolla, CA) and has five repeats of NF-B binding elements (T GGGGACTTTCC GC) next to the TATA box.
In Vitro T-Cell Proliferation Assay. Splenocytes from C57BL/6 (1 ϫ 10 6 cells/ml) were preincubated with various concentrations of compounds (0ϳ100 M) for 3 h and then transferred to 96-well plates (2 ϫ 10 5 cells/well) coated with anti-CD3 Ab (0.2 g/ml). Splenocytes were further incubated for 96 h. [ 3 H]Thymidine was added to each well, and plates were harvested after an additional 18 h of culture. Incorporation of thymidine into DNA was measured by beta counter (MicroBeta TriLux; PerkinElmer Life and Analytical Sciences, Waltham, MA).
Mixed Lymphocyte Reaction Assay. One-way mixed lymphocyte reaction (MLR) assays were performed as described previously (Strong et al., 1973) . In brief, C57BL/6 (H-2b) splenocytes (1 ϫ 10 5 cells/100 l/well) were cultured with an equal number of ␥-irradiated (800 rads) (Gammacell 3000 Elan; MDS Nordion, Ottawa, ON, Canada) BALB/c (H-2d) splenocytes in 96-well microplates. To examine the effect of KRM-III on MLR, mixed splenocytes were incubated for 3 days at 37°C in a 5% CO 2 incubator in the presence or absence of KRM-III (0ϳ50 M). Cells were pulsed with [ 3 H]thymidine for 12 h, and the amount of the incorporated [ 3 H]thymidine was measured by beta counter.
3-(4,5-Dimethylthiazol-2-ly)-2,5-dimethyltetrazolium Bromide Assays. Cells were suspended in RPMI 1640 medium (Invitrogen, Carlsbad, CA) or Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (5 ϫ 10 4 ϳ2 ϫ 10 5 cells/ml), and dispensed into 96-well plates at 100 l/well. CellTiter 96 Aqueous One Solution reagent (Promega, Madison, WI) was added to the assay wells at a ratio of 20 l of reagent per 100 l of culture medium. After incubation at 37°C for 4 h, absorbance was measured at 490 nm (SpectraMax microplate reader; Molecular Devices, Sunnyvale, CA).
Anti-CD3 Ab-Induced IL-2 Production. KRM-III was administered orally to BALB/c mice (200 l per mouse) 3 h before T-cell activation. The vehicle group was orally administered 0.2% CMC only. T cells were activated by intravenous inoculation of anti-CD3 Ab (125 ng/100 l/mouse). Two hours after anti-CD3 Ab injection, mice were bled via cardiac puncture, and the serum was collected and assayed for IL-2 by enzyme-linked immunosorbent assay (BD Biosciences, San Jose, CA).
Delayed-Type Hypersensitivity. On day 0, C57BL/6 mice were immunized intradermally with 400 g of methylated bovine serum albumin (mBSA; Sigma-Aldrich) in a 1:1 emulsion with complete Freund's adjuvant (CFA; Difco, Detroit, MI). Mice were orally administered KRM-III or CsA from day Ϫ1 to day 8 on a daily basis. On day 7, mice were challenged in one hind footpad with 100 g of mBSA in 20 l of phosphate-buffered saline (PBS) and in the opposite footpad with PBS alone as a control. Footpad swelling was measured 24 h after challenge using a vernier caliper (SigmaAldrich), and data are shown as the difference between the challenged footpad and the PBS control footpad. EAE Induction and Clinical Evaluation. To induce EAE by active immunization, female C57BL/6 mice were immunized subcutaneously at four sites on the flank, with a total of 100 g of MOG peptide emulsified in an equal volume of CFA (Difco) containing 4 mg/ml Mycobacterium tuberculosis H37 RA (Difco) on day 0. Subsequently, mice also received intraperitoneal injections of 400 ng of pertussis toxin (List Biological Laboratories Inc., Campbell, CA) on day 0 and day 2. Mice were orally administered KRM-III in 0.2% CMC on a daily basis from day 0 to day 25 or day 30 to evaluate its inhibitory effect on EAE progression. For evaluation of the KRM-III effect on established EAE, all of the mice were randomly assigned to each group on day 11, when more than 50% of animals in the cohort first exhibited clinical signs. KRM-III and vehicle were administered from day 11 after grouping. Clinical signs were monitored daily from day 7 postimmunization and scored based on the following criteria: 0, no detectable signs of disease; 0.5, distal limp tail; 1, complete limp tail; 1.5, limp tail and hind limb weakness; 2, unilateral partial hind paralysis; 2.5, bilateral hind limb paralysis; 3, complete bilateral hind limb paralysis; 3.5, complete bilateral hind limb paralysis and unilateral forelimb paralysis; 4, total paralysis of fore and hind limbs; 5, death. The onset of EAE was defined as the day a mouse showed a clinical score 0.5.
Histological Analysis. The EAE animals were anesthetized with an intraperitoneal injection of Zoletil 50 (27.78 mg/kg, tiletamine and zolazepam, 1:1) (Vibrac Laboratories, Carros, France) and xylazine (0.65 mg/kg), and perfused intracardially with 10 ml of normal saline, followed by 50 ml of fixative (4% paraformaldehyde in PBS). The spinal cord segments of cervical and lumbar enlargement were removed and postfixed in 4% paraformaldehyde in PBS for 1 day and embedded in the paraffin block. Five spinal cord sections were randomly selected from each segment. Sections (7-m thick) were prepared and then stained with Luxol fast blue and cresyl violet. Cresyl violet was used to stain the infiltrated inflammatory cells such as lymphocytes. The image of gray matter was removed before quantification because the dye also stains the Nissl body of the neuron. For the quantification of the areas for inflammatory cells stained with cresyl violet, the green channel of the color image was separated. The image of myelin sheath stained for Luxol fast blue was removed with color separation. The background patches have much higher gray values than inflammatory cells, and they were removed during segmentation. The pixels with gray values under a given threshold were segmented and measured by using image analysis software (ImageAnalysis Pro, version 3.0; SIS Muenster, Germany).
MOG-Specific T-Cell Response in EAE Model. Ten days after immunization, draining lymph node (DLN) cells (axillary and inguinal) were isolated and cultured with 25 g/ml MOG 35-55 peptide for 96 h in 96-well flat-bottom plates at a concentration of 5 ϫ 10 5 cells/well in complete RPMI 1640 medium (Invitrogen) containing 10% heat-inactivated fetal calf serum, 1 mM glutamine, 1% penicillin-streptomycin, 1 mM nonessential amino acids, and 5 ϫ 10 Ϫ5 M 2-mercaptoethanol. Cells were pulsed with [ 3 H]thymidine (GE Healthcare, Little Chalfont, Buckinghamshire, UK) at 0.5 Ci/well for the final 18 h before harvest. Incorporation of thymidine into DNA was measured by liquid scintillation counting (Luminometer counter; PerkinElmer Life and Analytical Sciences), and the mean was calculated from triplicate wells.
Single-Dose Pharmacokinetics and Detection of KRM-III. For single-dose pharmacokinetics study, female C57BL/6 mice were orally administered 10 mg/kg KRM-III in 0.2% CMC. Plasma levels of KRM-III were determined at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, and 24 h after oral administration. Two mice were assigned for each time point. To determine blood levels of KRM-III after single and repeated dosing, mice were administered 20 or 100 mg/kg KRM-III in 0.2% CMC. Twenty-four hours after last dosing, mice were terminated and blood level of KRM-III was determined. KRM-III concentrations in were preincubated with various concentrations of KRM-III (0ϳ50 M) for 3 h and activated by either anti-CD3 Ab (1 g/ml) or PMA (5 ng/ml) plus ionomycin (500 ng/ml). Jurkat cells were further incubated for 24 h, harvested, and assayed for luciferase activity. Data are representative of five independent experiments. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison test. Significance compared with vehicle group is shown as ‫,ء‬ p Ͻ 0.05 and ‫,ءء‬ p Ͻ 0.01.
Fig. 2. KRM-III inhibits TCR-induced proliferation and MLR.
A, splenocytes from C57BL/6 (1 ϫ 10 6 cells/ml) were preincubated with various concentrations of KRM-III (0ϳ100 M) for 3 h and transferred to 96-well plates (2 ϫ 10 5 cells/well) coated with anti-CD3 Abs (0.2 g/ml). Splenocytes were further incubated for 96 h and [ 3 H]thymidine was added 18 h before harvest. Data are representative of three independent experiments. B, C57BL/6 (H-2b) splenocytes (1 ϫ 10 5 cells/well) were cocultured with an equal number of ␥-irradiated (800 rads) BALB/c (H-2d) splenocytes in 96-well microplates. Mixed splenocytes were incubated for 3 days at 37°C in a 5% CO 2 incubator in the presence or absence of KRM-III (0ϳ50 M). Cells were pulsed with [ 
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at ASPET Journals on April 3, 2017 jpet.aspetjournals.org plasma were analyzed by protein precipitation and liquid chromatography-mass spectrometry/mass spectrometry (LC/MS/MS). Acetonitrile containing internal standard (IS) dextromethorphan solution (1 g/ml) (Sigma-Aldrich) was added to each sample and mixed at the ratio of 2:1. After centrifugation, the supernatants (5 l) were injected into HPLC column for LC/MS/MS analyses. The HPLC system consisted of a LC-20AD binary pump system (Shimadzu, Tokyo, Japan) and an API3200 triple quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, Concord, ON, Canada) equipped with a TurboIonSpray source. Chromatographic separation was achieved on a Xterra C 18 column (2.1 mm ϫ 50 mm I.D, 3 m). The HPLC mobile phases consisted of 0.1% formic acid (A) and 90% acetonitrile in 0.1% formic acid (B). Electrospray ionization was performed in the positive mode with nitrogen as the nebulizing, turbo spray and curtain gas, with the optimum values set at 50, 50, and 20 (arbitrary units). Multiple reaction monitoring detection was employed using nitrogen as the collision gas (5 arbitrary units) with a dwell time of 150 ms for each transition; the transitions monitored were fragmentations of the protonated molecules at m/z 253.1 and 272.3 to their corresponding product ions at m/z 117.0 and 215.3 for KRM-III and dextromethorphan (IS), respectively.
Protein Binding Assay. The concentrated test compounds were added to the mouse plasma to give final concentrations of 200 and 2000 ng/ml and incubated at 37°C for 1 h (test solutions). An aliquot of the test compound spiked plasma was filtered through a Microcon filter device (molecular weight cutoff of 10 kDa) (Amicon Bioseparations, Bedford, MA) by spinning at 1300g for 30 min (quality control solutions). Ice-cold methanol containing an IS dextromethorphan was added to the test and quality control solutions, mixed by vortex for 5 min, and centrifuged at 12,000 rpm for 5 min. Clear supernatant was separated and analyzed for LC/MS/MS analysis.
Statistical Analysis. The significance of biochemical data including luciferase assay, proliferation, and cytokine assay was analyzed by analysis of variance (ANOVA) followed by Dunnett's multiple comparison test. Footpad swelling and disease onset data were analyzed for statistical significance by Mann-Whitney U test. The statistical significance of the difference between the curves of vehicleand KRM-III-treated groups in EAE was determined by ANOVA for repeated measures followed by Dunnett's multiple comparison tests. The maximal mean clinical scores were analyzed by ANOVA. Data regarding infiltration of inflammatory cells were analyzed by Student's t test. Prism 4.0 software (GraphPad Software Inc., San Diego, CA) was used for statistical analysis.
Results
KRM-III Inhibits TCR-and PMA/Ionomycin-Induced NFAT Activation and T-Cell Proliferation. In the search Fig. 3 . KRM-III inhibits TCR-induced IL-2 production of T cells in vivo. KRM-III in 0.2% CMC was administered orally to BALB/c mice at 10ϳ90 mg/kg (200 l per mouse, 5 mice per group) 3 h before T-cell activation. The vehicle group was orally administered 0.2% CMC only. T cells were activated in vivo by intravenous inoculation of anti-CD3 Ab (125 ng/100 l/ mouse). Two hours later mice were bled, and the serum level of IL-2 was measured by enzymelinked immunosorbent assay. Data are representative of three independent experiments, and data points represent the mean Ϯ S.D.; five mice were included per group. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison tests. Significance compared with vehicle group is shown as ‫,ءء‬ p Ͻ 0.01. Fig. 4 . KRM-III inhibits DTH. C57BL/6 mice were immunized intradermally with 400 g of mBSA in a 1:1 emulsion with CFA on day 0 and challenged with 100 g of mBSA in 20 l of PBS in one hind footpad on day 7. As the control, another footpad was challenged with PBS only, and PBS-induced swelling was subtracted from mBSAinoculated footpad swelling. Mice were orally administered KRM-III in 0.2% CMC from day Ϫ1 to day 8 on a daily basis. Footpad swelling was measured 24 h after challenge by using a vernier caliper. Data are representative of three independent experiments. Five mice per group were used. Statistical analysis was performed by Mann-Whitney U test, and significance compared with vehicle group is defined as ‫,ء‬ p Ͻ 0.05 and ‫,ءء‬ p Ͻ 0.01.
for novel agents that block TCR-induced signaling, a chemical library was screened in Jurkat T cells transiently transfected with NFAT reporter encompassing the NFAT binding sites and a minimal promoter of IL-2. From the primary screen, KRM-III was screened out to have an inhibitory effect on TCR-induced NFAT reporter activity (Fig. 1A) . To determine dose dependence, Jurkat T cells with the NFAT reporter plasmid were preincubated with various concentrations of KRM-III (0ϳ50 M) for 3 h, transferred to anti-CD3 Ab-coated plates, and incubated for 24 h. KRM-III inhibited TCR-induced NFAT promoter activation in a dose-dependent manner with an IC 50 of 5 M (Fig. 1B) . KRM-III also inhibited PMA/ionomycin-induced NFAT reporter activity with a similar range of IC 50 , suggesting that the target of KRM-III locates downstream of PMA/ionomycin-acting points (Fig.  1C) . To determine the selectivity of KRM-III for NFAT reporter activity, we also tested the KRM-III effect on PMA/ ionomycin-induced NF-B reporter activity. Up to 50 M KRM-III did not block NF-B reporter activity (Fig. 1D) . These results suggest that KRM-III specifically inhibits NFAT activation but not NF-B activity.
To determine whether KRM-III-mediated inhibition of NFAT activation leads to the reduction in TCR-induced proliferation, splenocytes from C57BL/6 were preincubated with various concentrations of KRM-III (0ϳ100 M) for 3 h and stimulated by transferring cells to anti-CD3 Ab-coated plates. KRM-III inhibited TCR-induced T-cell proliferation with an IC 50 of 4 M ( Fig. 2A) , consistent with the NFAT luciferase assay in Jurkat T cells. Moreover, KRM-III also inhibited one-way MLR with an IC 50 of 5 M, confirming that KRM-III inhibits TCR-induced signaling and subsequent proliferation (Fig. 2B) .
To differentiate this T cell-inhibitory effect from nonspecific cytotoxicity, cell viability was determined by 3-(4,5-dimethylthiazol-2-ly)-2,5-dimethyltetrazolium bromide assays. Twenty-four hours of incubation with KRM-III of up to 50 M did not reduce the viability in Jurkat T cells, Chang liver, COS-7 (SV40 transformed, African green monkey kidney cell), and colon cancer cell lines including HT29 and Colo201 (data not shown). These results suggest that the T cell-inhibitory effect of KRM-III is not due to nonspecific cytotoxicity.
KRM-III Inhibits TCR-Induced IL-2 Production of T Cells in Vivo.
To determine the in vivo efficacy of KRM-III on T cells, KRM-III was administered orally at several time points before in vivo T-cell activation with intravenous administration of anti-CD3 Ab. The level of T-cell activation was indirectly determined by measuring IL-2 levels in the blood. Our preliminary study indicated that IL-2 levels reached a maximum 2 h after anti-CD3 Ab administration, and the in vivo T cell-inhibitory activity of KRM-III was highest when KRM-III was administered 3 h before T-cell activation (data not shown). Various concentrations of KRM-III (10ϳ90 mg/kg) were administered orally to BALB/c mice 3 h before T-cell activation. Whereas the vehicle-treated group showed IL-2 levels in the range of 600ϳ900 pg/ml, KRM-III-treated mice showed much reduced IL-2 levels. CsA, a calcineurin inhibitor (Winkler, 2000) , was used as a T-cell inhibitor control and showed potent T cell-inhibitory activities with an ED 50 of 6.2 mg/kg. The ED 50 of KRM-III for the inhibition of anti-CD3-induced IL-2 production was 9.9 mg/kg, and IL-2 production was suppressed up to 98% at 90 mg/kg (p Ͻ 0.01) (Fig. 3) . These results indicate that orally administered KRM-III is fully functional in inhibiting T-cell activation in vivo.
KRM-III Inhibits DTH Response. To determine that KRM-III-mediated suppression of T-cell activation leads to the prevention of T cell-mediated immunopathological responses in vivo, we examined the effect of KRM-III on inflammation in DTH model. Mice were immunized with bovine serum albumin in 1:1 emulsion of CFA on day 0 and challenged on day 7. Footpad swelling was measured 24 h postchallenge. KRM-III of 90 mg/kg/day given from day Ϫ1 to day 8 showed 45.8% inhibition compared with the vehicle-treated group (p Ͻ 0.01), whereas CsA of 90 mg/kg/day exhibited 78% inhibition (p Ͻ 0.01) (Fig. 4) . This result suggests that KRM-III-mediated T-cell suppression inhibits inflammatory responses.
KRM-III Reduces Clinical Severity and Infiltration of Inflammatory Cells to the White Matter of Spinal
Cords in MOG-Induced EAE Mice. To evaluate the inhibitory effect of KRM-III on disease initiation and progression in MOG-induced EAE, C57BL/6 mice were orally administered KRM-III starting from the day of the first subcutaneous immunization with MOG 35-55 peptide to day 25 or day 30 on a daily basis. The vehicle-treated group started to show disease onset from day 10 to 12 and reached the maximal level on day 20 to 22 (Fig. 5, A-C) . Whereas 90 mg/kg/day of CsA almost completely inhibited EAE progression, 90 mg/kg/ day of KRM-III partially blocked EAE progression and reduced clinical severity comparable to 30 mg/kg/day of CsA (Fig. 5A; Table 1 ). In dose-dependence test, most of the vehicle-treated mice (87.5%) showed severe EAE with maximal clinical scores ranging between 2.6 and 5 (Table 2 ). In contrast, the majority of the KRM-III (100 mg/kg/day)-treated group displayed a moderate level of disease severity (0.5-2.5), resulting in a reduced mean maximal clinical score (1.85 Ϯ 0.13, p Ͻ 0.05 versus vehicle). The low-dose KRM-III-treated group (20 mg/kg/day) seemed to have lower mean maximal clinical scores than the vehicle group but did not reach the clinical significance (Table 2) . Statistical significance of the clinical score curves between the vehicle-treated group and KRM-III-treated group was assessed from day 11, and the high-dose KRM-III-treated group (100 mg/kg/day) revealed a significant difference compared with the vehicletreated group (p Ͻ 0.01) (Fig. 5B) . However, the disease onset was not significantly different between both of the KRM-IIItreated groups (14.14 Ϯ 3.97 for 100 mg/kg/day group; 13.25 Ϯ 2.6 for 20 mg/kg/day group) and the vehicle-treated group (12.38 Ϯ 1.30). In summary, KRM-III reduced clinical severity but did not delay the onset of EAE.
EAE is characterized by massive demyelination of the myelin sheath and infiltration of peripheral leukocytes into the brain and spinal cords. To understand the nature of the KRM-III effect on the pathological process of EAE, spinal cords including cervical and lumbar cord segments were isolated and observed for leukocyte infiltration. Mice were orally administered 100 mg/kg/day of KRM-III from day 0 to day 19 and sacrificed on day 20 for histological analysis. Spinal cords from KRM-III-treated mice exhibited reduced infiltration of inflammatory cells into white matter of spinal cords, but statistical significance was only observed in lumbar segments (Fig. 6) .
To investigate the therapeutic effect of KRM-III, KRM-III was administered daily from the day of EAE onset (day 11) until day 30 (Fig. 5C ). All mice were randomly enrolled into each group on day 11 when more than 50% of mice started to show clinical signs. The mean clinical scores of each group on day 11 were not statistically different (data not shown). Although the inhibitory effect was not as prominent as when it was administered from day 0, nonparametic ANOVA for repeated measures from day 11 indicated that KRM-III significantly reduced clinical signs (p Ͻ 0.05 versus vehicle) (Fig.  5C ). In conclusion, these data suggest that KRM-III has therapeutic, although not as profound as prophylactic, effects in the EAE model. KRM-III Treatment Inhibits MOG-Specific T-Cell Proliferation. T cells have long been reported to participate in EAE pathogenesis (Traugott et al., 1983; Olsson, 1995) . To evaluate the KRM-III effect on MOG-specific T-cell response, C57BL/6 mice were orally administered KRM-III (20, 100 mg/kg/day) or CsA (20, 100 mg/kg/day) from the day of the first immunization with MOG. On day 10, DLN cells were isolated and cultured in the presence or absence of MOG for 3 days, and proliferation was measured by [ 3 H]thymidine incorporation assay. Whereas the vehicle-treated group showed 4-fold increased proliferation of DLN cells in response to MOG, high-dose KRM-III-treated mice (100 mg/kg/ day) showed strongly reduced proliferation comparable to the low-dose CsA group (20 mg/kg/day) (p Ͻ 0.01 versus vehicle) (Fig. 7) . On the other hand, the low-dose KRM-III group (20 mg/kg/day) did not show significant proliferation inhibition of DLN cells (Fig. 7) in agreement with clinical severity data ( Table 2 ). This result implies that KRM-III-mediated inhibition of T-cell activation and proliferation is one of the mechanisms of KRM-III-mediated attenuation of EAE onset and progression. Pharmacokinetic and Pharmacodynamic Profiles of KRM-III. C57BL/6 mice were orally administered 10 mg/kg KRM-III. Blood was collected by heart puncture at 10 different time points throughout a 24-h period. KRM-III had a t 1/2 of 7.09 h and a C max of 0.9 M (0.23 g/ml) ( Table 3) . Terminal blood levels of KRM-III after 10 days of repeated dosing were measured. Blood level of KRM-III 24 h after last dosing was 31 Ϯ 0.017 ng/ml and 64 Ϯ 0.004 ng/ml at 20 and 100 mg/kg/day, respectively, which were not different from single dosing (data not shown). This result suggests that orally introduced KRM-III does not accumulate in vivo. According to the protein-binding assay, KRM-III was highly protein-bound in mouse plasma and only 1 to 2% of KRM-III seemed to be free at concentrations of 0.2 to 2 g/ml (Table 4) .
Discussion
In this study, we demonstrated the inhibitory effect of KRM-III on TCR-and PMA/ionomycin-induced NFAT activation, TCR-induced proliferation, and MLR. KRM-III specifically inhibited PMA/ionomycin-induced NFAT activation but not NF-B. Oral administration of KRM-III inhibited T-cell activation in vivo as determined by markedly reduced IL-2 levels after T-cell activation. KRM-III showed both prophylactic and therapeutic effects in the EAE model as demonstrated by reduced disease progression and morbidity. DLN cells from KRM-III-treated mice showed much reduced proliferation in response to MOG in vitro, suggesting that T-cell activation/proliferation was blocked by in vivo KRM-III treatment. Tissue sections of spinal cords also showed decreased infiltration of inflammatory cells into the white matter, suggesting that T-cell inhibition eventually prevented amplification of the inflammatory process.
KRM-III inhibited both TCR-and PMA/ionomycin-induced NFAT activation (Fig. 1, B and C) . This result suggests that the KRM-III target exists downstream of PMA and ionomycin-acting points. The IL-2 promoter contains an NFAT-activating protein 1 (AP-1) composite site, which consists of adjacent binding sites for both NFAT and AP-1 transcription factors (Maciá n et al., 2001 (Maciá n et al., , 2005 . Because the NFAT reporter used in this study contains NFAT and AP-1 binding sites, inhibition of AP-1 activation via the PKC/Ras/MAPK/ AP-1 pathway could also reduce TCR-induced NFAT activation (Chang et al., 2005) . However, up to 50 M KRM-III did not block TCR-induced phosphorylation of p42/44 MAPK (data not shown), which means that KRM-III does not inhibit the signaling pathway upstream of MAPK. Therefore, it is possible that KRM-III might affect NFAT activation either directly or indirectly by working downstream of MAPK. Meanwhile, KRM-III did not block PMA/ionomycin-induced NF-B activation (Fig. 1D) . This result suggests that the KRM-III target does not reside in the lineage of PKC/ CARMA-1/TRAF6/IKK/NF-B (Rawlings et al., 2006; Thome, 2008) and is not the overlapping signaling component(s) of NFAT-and NF-B activation. In conclusion, the KRM-III target resides neither in the lineage of PKC to NF-B activation nor in that of PKC to MAPK activation, and it remains to be determined.
KRM-III-mediated inhibition of T-cell activation and proliferation seems to ascribe from T cell-signaling inhibition rather than from nonspecific cytotoxicity. Specific inhibition of NFAT activation, but not NF-B activation by KRM-III, supports this notion (Fig. 1, C and D) . Moreover, KRM-III did not reduce cell viability of a broad range of cells including T cells and liver, kidney, and colon cells (data not shown). Because NFAT is widely expressed and participates in transcriptional activation of various cytokines (Maciá n et al., 2001 (Maciá n et al., , 2005 , we cannot exclude the possibility that KRM-III might also inhibit NFAT activation in other immune cells.
KRM-III induced 98% inhibition on anti-CD3-induced IL-2 production at 90 mg/kg, suggesting that orally administered 
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at ASPET Journals on April 3, 2017 jpet.aspetjournals.org KRM-III is functional in inhibiting T-cell activation (Fig. 3) . To determine whether KRM-III-mediated T-cell inhibition could also inhibit T cell-dependent disease progression, we observed the KRM-III effect in mice afflicted with EAE. Oral administration of KRM-III, started on the day of immunization with MOG peptide, attenuated clinical severity (Fig. 5, A and B; Tables 1 and 2), which correlated with decreased infiltration of inflammatory cells into the white matter of spinal cords (Fig. 6 ). Myelin-specific T cells have been implicated in EAE (Olsson, 1995) . T helper 1 cells secrete proinflammatory cytokines such as tumor necrosis factor-␣, and interferon-␥, which trigger immunopathological cascade leading to the damage of the myelin sheath and the axon (Kuchroo et al., 1993; Rudick et al., 1997; McFarland and Martin, 2007) . DLN cells from KRM-III-treated mice (100 mg/kg/day) showed reduced proliferation in response to MOG, suggesting that T cell is well suppressed by a high dose of KRM-III in vivo (Fig. 7) . This result also reflects DTH (Fig.  4) and EAE (Fig. 5A) , where 90 mg/kg/day of KRM-III attenuated disease severity comparable to 30 mg/kg/day of CsA. Based on reduced T cell-proliferative response to MOG, we can conclude that KRM-III-mediated T-cell suppression would be one of the major factors that inhibit EAE progression.
Single-dose pharmacokinetics of KRM-III suggests that KRM-III decays fast and has C max of 0.9 M at 10 mg/kg (Table 3 ). This might explain why the in vivo EAE-inhibitory effect was not as remarkable as the in vitro (Fig. 2) and in vivo short-term, T cell-inhibitory effect (Fig. 3) . Because blood KRM-III levels after 10 days of repeated dosing were not quite different from single dosing, KRM-III does not seem to accumulate.
Drug-plasma protein binding is one of the many factors that influence bioavailability of a drug. Efficacy, distribution, and elimination of a drug can be affected by the reversible binding of the drug to plasma proteins, such as albumin and acid glycoprotein. Our data suggest that KRM-III is highly protein-bound in mouse plasma (Table 4) . It is possible that the pharmacodynamic effects of KRM-III are dictated by unbound KRM-III, which may explain why the high-dose KRM-III-treated group (100 mg/kg/day) displayed a moderate improvement of disease severity.
In conclusion, KRM-III is a novel compound with T cellinhibitory activity. KRM-III effectively prevented T-cell activation and proliferation in vitro and in vivo. Its T cell-inhibitory activity was specific to NFAT activation but not to NF-B. In the EAE model, KRM-III not only inhibited T-cell proliferation but also resulted in decreased disease progression and morbidity. Based on the facts that 1) KRM-III is orally active, 2) KRM-III inhibits T-cell activation in vivo, and 3) KRM-III-mediated T-cell inhibition attenuated disease severity in DTH and EAE, we suggest that KRM-III is a potential therapeutic agent for the treatment of T cell-mediated diseases. Further clarification of KRM-III target and target-based optimization as well as improvements in pharmacokinetic and pharmacodynamic profiles may generate more potent drug candidates. T cells from the KRM-III-treated group respond less to MOG. C57BL/6 mice were immunized subcutaneously at four sites of the flank with 100 g of MOG in 1:1 emulsion of CFA on day 0 and subsequently sensitized with pertussis toxin (400 ng) intraperitoneally on day 0 and day 2. Mice were orally administered KRM-III (20, 100 mg/kg/day) or CsA (20, 100 mg/kg/day) in 0.2% CMC from day 0 to day 9. Ten days after immunization (day 10), DLN cells were isolated and cultured in 96-well plates (5 ϫ 10 5 cells/well) with or without MOG peptide (25 g/ml) for 4 days. Cells were pulsed with [ 3 H]thymidine for the last 18 h of incubation. Data are representative of two independent experiments. n ϭ 5 mice per group: ‫,ءء‬ p Ͻ 0.01, compared with vehicle control by one-way ANOVA. 
